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Although Ab peptides are causative agents in Alz-
heimer’s disease (AD), the underlying mechanisms
are still elusive. We report that Ab42 induces a trans-
lational block by activating AMPK, thereby inhibiting
the mTOR pathway. This translational block leads to
widespread ER stress, which activates JNK3. JNK3
in turn phosphorylates APP at T668, thereby facili-
tating its endocytosis and subsequent processing.
In support, pharmacologically blocking translation
results in a significant increase in Ab42 in a JNK3-
dependent manner. Thus, JNK3 activation, which
is increased in human AD cases and a familial AD
(FAD) mouse model, is integral to perpetuating
Ab42 production. Concomitantly, deletion of JNK3
from FAD mice results in a dramatic reduction in
Ab42 levels and overall plaque loads and increased
neuronal number and improved cognition. This
reveals AD as a metabolic disease that is under tight
control by JNK3.
INTRODUCTION
Ab peptide accumulation is a hallmark of Alzheimer’s disease
(AD), being released from neurons via extracellular and sub-
sequent intramembrane cleavage reactions of the amyloid
precursor protein (APP) (Tanzi and Bertram, 2005). Recent find-
ings suggest that soluble oligomeric are the pathogenic forms,
eliciting neurotoxic effects that culminate in synaptic dysfunction
and neuronal loss (Haass and Selkoe, 2007). Discovery of Prp
and EphB2 as receptors for oligomeric Ab42 (Cisse´ et al.,
2011; Laure´n et al., 2009) provides support for the view that
oligomeric Ab peptides could function as neurotoxic ligands,
initiating diverse cellular signaling events that range widely,
including inflammation, mitochondrial dysfunction, oxidative
stress, apoptosis/autophagy, intracellular calcium imbalance,
and a block in LTP (Koo and Kopan, 2004), any of which could824 Neuron 75, 824–837, September 6, 2012 ª2012 Elsevier Inc.contribute to AD pathology. Themechanism bywhich oligomeric
Ab peptides elicit such diverse cellular outcomes, however, has
remained elusive.
Here, we report that oligomeric Ab42 exerts such diverse
effects in part by inducing a translational block, which is accom-
panied by ER stress as indicated by increased phosphorylation
of Eif2a in hippocampal neurons. Increased Eif2a phosphoryla-
tion was reported to inhibit the late phase of LTP and memory
acquisition (Costa-Mattioli et al., 2007, 2009). Once induced,
ER stress activates Unfolded Protein Response (UPR), in-
ducing widespread secondary reactions, some of which include
changes in inflammatory responses as well as cell survival
programs (Ron andWalter, 2007), the often reported phenotypes
in AD.
As part of UPR, ER stress activates the JNK pathway (Urano
et al., 2000). JNK proteins, especially JNK3, a brain-specific
JNK isoform, have been reported to play roles under neurode-
generative conditions, such as Parkinson’s disease: deletion of
JNK3 in combination with JNK2 prevented loss of dopaminergic
neurons after MPTP administration (Hunot et al., 2004). Deleting
JNK3 also resulted in a significant increase in neuronal and olio-
godendrocyte survival after traumatic injuries in the CNS (Beffert
et al., 2006; Li et al., 2007). Although JNK activation has been
reported in human AD brains, its role in AD pathology develop-
ment remained unclear. To address this question, we analyzed
an AD mouse model with and without JNK3. Our results indicate
that JNK3 activation is integral to AD pathology, where JNK3
deletion restores the translational block induced by oligomeric
Ab42 and the effect of UPR.RESULTS
Oligomeric Ab42 Induces a Translational Block by
Activating AMPK, Thereby Inhibiting the mTOR Pathway
Oligomeric Ab42 inhibits LTP and impairs memory formation
in vivo (Cleary et al., 2005; Walsh et al., 2002), suggesting that
Ab peptides are pathogenic species that disrupt normal
synaptic function and cognition. Disrupting translational control
by disabling eif2a phosphorylation or deleting its kinase,
GCN2, also resulted in inhibition of LTP and memory acquisition
Figure 1. Oligomeric Ab42 Induced the Translational Block by Activating AMPK
(A) 6E10western blot of oligomeric Ab42 and the control Ab42R (reverse sequence) used in the study. Actual concentration of oligomeric species is approximately
250 nM in 5 mM total Ab42.
(B) Oligomeric Ab42 inhibits translation in rat hippocampal neurons. All 35S-methionine fluororadiograms were obtained from the same experiment.
(C) Quantification of 35S-methionine incorporation in (B). The rate of 35S-methionine incorporation in the control was regarded as 1.0. Data are represented as
means ± SEM. P values were calculated by Student’s t test: p% 0.001 for Ab42, p% 0.005 for Rapamycin, p% 0.001 for Thapsigargin, and p% 0.00001 for
Cycloheximide.
(D) Overnight treatment with 250 nM oligomeric Ab42 in metabolic experiments did not induce cell death in hippocampal neurons. Note that the majority of live
MAP2+ neurons failed to incorporate propidium iodide both in control and Ab42-treated cultures. Instead, oligomeric Ab42 induced neurite degeneration (arrow).
After propidium iodide incorporation while they were alive, cells were fixed and immunostained for MAP2 to identify neurons.
(E) Oligomeric Ab42 induces a translational block by activating AMPK, thereby inhibiting the mTOR pathway. Rat hippocampal neurons were treated with 250 nM
oligomeric Ab42, 0.5 mM Thapsigargin, and 10 nM Rapamycin for the indicated periods of time. Note that S792 phosphorylation in Raptor and S1387 phos-
phorylation in TSC2, both of which are phosphorylated by AMPK, were also increased. S6K phosphorylation declined gradually with oligomeric Ab42, suggesting
mTOR inhibition. Oligomeric Ab42 also induces ER stress based on Eif2a phosphorylation.
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Ab Activates AMPK(Costa-Mattioli et al., 2005, 2007). Considering these parallel
findings, we decided to ask whether Ab42 could induce a trans-
lational block. To address the question, we measured the
amount of 35S-methionine incorporation in rat hippocampal
neurons after treatment with 5 mM Ab42 overnight. It should be
noted that the actual concentration of oligomeric Ab42 in 5 mM
Ab42 was estimated to be 250 nM (Figure 1A). As controls,
parallel cultures were treated with Cycloheximide, a protein
synthesis inhibitor, and Rapamycin and Thapsigargin, agents
whose actions impinge on the translational machinery. Oligo-
meric Ab42 treatment at 250 nM inhibited 35S-methionine incor-
poration by 44% (n = 3–5, p% 0.0001), while 10 nM Rapamycin
and 0.5 mM Thapsigargin reduced 35S-methionine incorporation
by 70%–72% (n = 3–5, p% 0.01 and 0.001, respectively, Figures
1B and 1C). The effect of 20 mM Cycloheximide was virtually
complete, blocking translation by 99% (n = 3–5, p % 0.00001).
The reduction in 35S-methionine incorporation was not due to
cell death induced by Ab42, since there were very few MAP2+
neurons that incorporated propidium iodide when alive (Fig-
ure 1D). We therefore conclude that Ab42 induces a translational
block in cultured neurons.
Rapamycin inhibits translation by blocking recruitment of
mTOR to the translational initiation complex (Ma and Blenis,
2009) and Thapsigargin by inducing ER stress, which results in
phosphorylation of Eif2a (Costa-Mattioli et al., 2009; Ron and
Walter, 2007). In order to understand whether the mechanism
by which oligomeric Ab42 causes a translational block resem-
bles that of Thapsigargin or Rapamycin, we examined the
temporal changes in the phosphorylation status of various
proteins that are known to be involved in the mTOR pathway
and UPR in hippocampal neurons. Oligomeric Ab42 induced
a rapid increase in AMP-activated protein kinase a (AMPKa)
phosphorylation (Figure 1E). Rapamycin and Thapsigargin also
activated AMPK, but the kinetics of its activation differed from
that by oligomeric Ab42. Monomeric and fibrillar forms of Ab42
did not activate AMPK in hippocampal neurons (Figure 1F).
AMPK was shown to phosphorylate TSC2 and Raptor at
S1387 and S792, respectively, thereby inhibiting the mTOR
pathway (Gwinn et al., 2008; Inoki et al., 2003). Indeed, both
TSC2 and Raptor were phosphorylated by oligomeric Ab42 in
kinetics similar to that of AMPK phosphorylation, and phosphor-
ylation of S6 kinase decreased gradually over time (Figure 1E).
We hypothesized that oligomeric Ab42 inhibits the mTOR
pathway in part by activating AMPK. Indeed, when AMPK activa-
tion was inhibited with 5 mM Compound C as indicated by
a reduction in phospho-RaptorS792 levels, S6K phosphorylation
was increased significantly with oligomeric Ab42 at all the time
points tested (Figure 1G). These results together suggest that
oligomeric Ab42 initiates a translational block by inhibiting the
mTOR pathway via a mechanism that involves AMPK activation.
It should also be noted that oligomeric Ab42 increased phos-
phorylation of Eif2a, although the extent of its increase is much(F) Monomeric and fibrillar forms of Ab42 fail to activate AMPK significantly. Rat hi
the indicated periods of time.
(G) AMPK is necessary for oligomeric Ab42 to inhibit the mTOR pathway. S6K pho
Compound C. Hippocampal neurons were treated with vehicle or 5 mMCompound
As a control for Compound C, p-RaptorS792 blot is also shown along with total S
826 Neuron 75, 824–837, September 6, 2012 ª2012 Elsevier Inc.less than that by Thapsigargin (Figure 1E).We interpret this result
as suggesting that oligomeric Ab42-mediated translational block
leads to UPR.
JNK3-Dependent Phosphorylation of APP Increases
APP Endocytosis and Processing
UPRwas shown to activate the JNKpathway (Urano et al., 2000).
We hypothesized that once UPR is induced, it activates JNK3,
which in turn promotes further APP processing by phosphory-
lating it at T668P in neurons. Indeed, Thapsigargin and Rapa-
mycin induced JNK3 activity in rat hippocampal neurons: JNK3
activity increased 5–30 min after treatments, which was sus-
tained for up to 3 hr (Figures 2A and 2B).
APP has a MAP kinase phosphorylation site at T668P, which
becomes phosphorylated only in neurons (Iijima et al., 2000).
We hypothesized that JNK3-mediated phosphorylation of APP
results in internalization of APP into endosomal compartments,
wherein it undergoes amyloidogenic processing. In support,
Ab42 has been detected in endosomes via immuno-EM in AD
cases (Takahashi et al., 2002).Wefirst askedwhether JNK3phos-
phorylated T668P in vitro. Active JNK3 indeed phosphorylated
APP at T668P in vitro, as JNK3 failed to phosphorylate APP
when T668 was mutated to A668 (Figure 2C). Active CDK5/p35
complex, on the other hand, still phosphorylated the mutant
APPA668, suggesting that JNK3 phosphorylates T668P, while
CDK5/p35 phosphorylates sites other than T668P.
As a way to address whether JNK activation affects APP inter-
nalization, we asked whether JNK activation alters the amount of
the full-length APP on the cell surface. In addition, since
Anisomycin activates p38 besides JNK, cortical neurons
were preincubated for 1 hr with 1 mM cell-permeable JNK-
Interacting-Protein (JIP) peptides that inhibit JNK specifically
(Barr et al., 2002; Farı´as et al., 2009), while control cultures
were treated with cell-permeable control peptides. JIP peptides,
TAT-TI-JIP, contain 22-amino acids, which were shown to be
necessary for JIP to inhibit JNK activation (Dickens et al.,
1997). The JIP peptides were alsomodified tomake it permeable
to mammalian cells by adding 10 amino acid sequences of HIV-
TAT protein (Bonny et al., 2001; Schwarze et al., 1999). After
treatments with 50 ng/ml Anisomycin at 37C for 0, 5, 15, and
30 min, cells were subjected to cell-surface biotinylation on ice
for 30 min, and the amount of the cell-surface-located, bio-
tinylated, full-length APP was determined following Neutravidin
pulldown and subsequent western blotting for APP. In control
cultures, Anisomycin treatment resulted in a rapid increase in
biotinylated APP on the cell surface, which was followed by
a gradual reduction in the amount of cell-surface biotinylated
APP, reaching 52% of the original APP level by 30 min (Figures
2D and 2E). In contrast, when the endogenous JNKwas inhibited
by the JIP peptides as evidenced by the reduction in phospho-
cjun levels, cell-surface biotinylated APP levels remained
unchanged (Figures 2D and 2E). Anisomycin treatment alsoppocampal neurons were treated with 250 nMmonomeric and fibrillar Ab42 for
sphorylation was increased with Ab42 when AMPK activation was inhibited by
C for 30min prior to oligomeric Ab42 addition for the indicated amount of time.
6K and Raptor protein blots.
Figure 2. JNK-Mediated Phosphorylation of T668P Regulates APP Internalization and Processing
(A) Both Thapsigargin and Rapamycin activate JNK3 in rat hippocampal neurons. At the indicated times, the lysates were harvested and subjected to immu-
noprecipitation/kinase assays using GST-c-jun as a substrate. As controls, JNK3 western results are also shown.
(B) Quantification of 32P-GST-c-jun in (A). The data are represented as means ± SEM (n = 2–3).
(C) JNK3 phosphorylates APP at T668P in vitro. Purified GST-APPICD proteins were subjected to in vitro kinase assays in the presence of 32P-g-ATP using active
JNK3, p38, CDK5/p35, and GSK-3b according to the manufacturer’s instructions (Millipore). Only JNK3 and CDK5 phosphorylated APP, while p38 and GSK-3b
did not. Note that JNK3 failed to phosphorylate APP, when T668wasmutated to A, but CDK5/p35-dependent phosphorylation still remained. These data suggest
that JNK3 phosphorylates T668P, while CDK5/p35 phosphorylates sites other than T668P.
(D) JNK facilitates internalization of APP from the cell surface. For activation of the endogenous JNK pathway, hippocampal neurons were treated with 50 ng/ml
Anisomycin for the indicated amount of time. After Anisomycin treatment, cells were subjected to cell-surface biotinylation on ice, and the biotinylated APP on the
cell surface was detected following Neutravidin pulldown. Note that the amount of APP on the cell surface was increased initially, which was followed by
a decrease with Anisomycin treatment over time. To test whether the changes in APP trafficking were due to JNK activation, a parallel set of cultures were treated
with cell-permeable JNK inhibitor, TAT-TI-JIP peptides. Control cultures were treatedwith cell-permeable control peptides.When JNK activation was inhibited as
indicated by the reduction in p-cjun and p-APPT668 levels, the amount of APP on the cell surface remained the same with Anisomycin treatment over time. These
results suggest that JNK activation is necessary for inducing APP internalization.
(E) Quantification of cell-surface biotinylated APP after Anisomycin treatment. Data are represented as means ± SEM. p values were calculated by
Student’s t test.
(F) JNK activation increased APP processing following internalization. The amount of CTF increased with Anisomycin treatment. Following cell-surface
biotinylation on ice, neurons were incubated with Anisomycin for 2 hr at 37C. At the end of incubation, biotins left on the cell surface were removed by treating
cells with 50 mM DTT before protein extracts were prepared. The internalized APP and its products were subsequently detected by Neutravidin pulldown
followed by APP western blotting as well as 6E10 immunoprecipitation followed by Strepavidin-HRP blotting.
(G) T668P phosphorylation is necessary for APP internalization and processing. Anisomycin treatment reduced the full-length, biotinylated wild-type APP from
the cell surface, while it increased the amount of biotinylated CTF. On the other hand, Anisomycin failed to induce internalization of and CTF production from the
A668P mutant. 293T cells were transfected with the wild-type, full-length APP, and A668P mutant and subjected to the same cell-surface biotinylation and
internalization as with cortical neurons. Also shown are p-JNK and JNK blots in addition to a loading control, ERK blots.
(H) Quantification of the data in (G). Data are represented as means ± SEM. p values were calculated by Student’s t test.
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Ab Activates AMPKincreased the extent of APP phosphorylation at T668 in control
cultures, while it did not in cultures treated with JIP peptides.
These results suggest that JNK activation induces rapid traf-
ficking of APP to the cell surface and subsequent internalization
in part by phosphorylating APP at T668.In order to test whether a JNK-mediated increase in internali-
zation results in greater APP processing, cortical neurons were
subjected to cell-surface biotinylation using a reversible biotin
crosslinker, Sulfo-NHS-SS-Biotin, prior to treating them for 2 hr
with Anisomycin and also inducing internalization at 37C. AtNeuron 75, 824–837, September 6, 2012 ª2012 Elsevier Inc. 827
Figure 3. JNK3 Activity Is Increased in
Human AD and FAD Cases
(A) JNK3 activity is increased in human AD cases
compared to age-matched controls. The lysates
from human frontal cortices were subjected to
JNK3 immunoprecipitation/kinase assays using
GST-c-jun as a substrate. As a control, JNK3 and
6E10 western blots are also shown.
(B) Quantification of 32P-GST-c-jun in (A). The data
are represented as means ± SEM.
(C) JNK3 activity is higher in FAD mice compared
to normal mice at 5–6 months. Lanes 1 to 4
represent four different FAD:JNK3+/+ mice, and
lanes 5 to 8 represent JNK3+/+ mice.
(D) Quantification of 32P-GST-c-jun in (C). The data
are represented as means ± SEM.
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Ab Activates AMPKthe end of the incubation time, remaining biotins on cell-surface
proteins were removed by treating cells with 50 mM DTT on ice,
thus allowing selective detection of the internalized, cell-surface
biotinylated proteins via Neutravidin pulldown/APP blotting or
Streptavidin-conjugated secondary antibody after immunopre-
cipitation with 6E10 (Figure 2F, Yu et al., 2011). Anisomycin treat-
ment increased the amount of biotinylated C-terminal fragment
(CTF) production significantly, which correlated with increased
T668 phosphorylation on CTF (Figure 2F). These results together
suggest that JNK activation rapidly induces APP internalization/
endocytosis, thereby facilitating APP cleavage reactions.
We next determined whether T668P phosphorylation by JNK
is required for the internalization and processing of APP. For
this, the full-length APP and a point mutant, A668, were trans-
fected into 293T cells and subjected to cell-surface biotinylation
and internalization assays as described above. The amount of
the full-length APP that was biotinylated on the cell surface
decreased with 30 min Anisomycin treatment in the wild-type,
but not in the A668P mutant, suggesting that phosphorylation
of T668P facilitates the internalization of the full-length receptor
(Figures 2G and 2H). Upon internalization, a greater amount of
biotinylated CTF was detected with the wild-type APP after
Anisomycin treatment, but not with the A668P mutant (Fig-
ure 2G). These results together suggest that T668P phosphory-
lation by JNK is necessary for APP to be internalized into endo-
somes and processed to generate Ab peptides.
JNK3Activity Is Increased in HumanADCases aswell as
in FAD Mice
Since our in vitro data suggested that JNK-dependent phos-
phorylation of T668P in APP is necessary for APP internalization
and processing, we wished to determine the role of JNK3 in AD
pathology by deleting JNK3 from an AD mouse model. We
focused on JNK3, since unlike JNK1 and 2, JNK3 is enriched
in the nervous system and plays a role under pathological condi-
tions but has little effect on normal development (Kuan et al.,
1999; Yang et al., 1997). As our first step toward addressing
the question, we asked whether JNK3 activity increased in
human AD cases as well as in 5XFAD (henceforth called828 Neuron 75, 824–837, September 6, 2012 ª2012 Elsevier Inc.‘‘FAD’’) mice in comparison to normal human and mice cases,
respectively, by performing immunoprecipitation/kinase assays
using JNK3-specific antibody. The specificity of JNK3 antibody
has been demonstrated (Li et al., 2007). FAD mice express
mutant human APP (Swe/Fl/Lon) and PS1 (M146L/L286V)
genes, each under a neuronal Thy1 promoter, producing more
Ab42 than Ab40 (Oakley et al., 2006). Indeed, JNK3 activity
increased by 34% in human AD compared to normal cases
(n = 9–13, p % 0.05), and by 27% in FAD:JNK3+/+ mice
compared to normal JNK3+/+ mice at 5–6 months (n = 4, p %
0.05; Figures 3A–3D). These results suggest that JNK3 activity
correlates with AD pathology.
JNK3 Is the Principle JNK IsoformActivated in FADMice
We next determined where active JNK is localized in FAD brains
using active JNK or p-JNK antibody in immunohistochemistry.
Beginning at 2–3months, the timewhen plaques begin to appear
in FAD:JNK3+/+ mice, p-JNK signals were predominantly
detected near plaque structures, colocalizing with 8E5 immuno-
reactivity (Figures 4A, 4B, and 4D), a dystrophic neurite marker
(Games et al., 1995). p-JNK signals were similarly reported to
colocalize with 6E10 immunoreactivity in Tg2576/PS1M146L
mice (Braithwaite et al., 2010). Also in aged monkey, p-JNK
signals were detected near plaque structures (Figure 4C), sug-
gesting that accumulation of active JNK near plaque structures
is a common feature in primates as well. When FAD:JNK3/
mouse brains were analyzed, on the other hand, p-JNK signals
were reduced dramatically, to near background levels, and
colocalization of p-JNK with 8E5 was not detected (Figures 4A
and 4B). These results indicate that JNK3 is the principle JNK
isoform that is activated in FAD mice.
A closer observation into FAD:JNK3+/+ mice revealed that
p-JNK signals were detected predominantly at sites of neuritic
damage assessed by 8E5 staining (Figure 4D): at 6 months,
p-JNK signals are rarely detected in the soma. This result
suggests that JNK3 becomes activated in damaged and degen-
erating neuritic processes, in agreement with previous reports
(Abe et al., 2009; Cavalli et al., 2005; Muresan and Muresan,
2005). It should be noted that JIP and JNK3 have been reported
Figure 4. JNK3 Is the Principle JNK Isoform
that Is Activated in FAD Mice
(A) JNK3 is the predominant JNK isoform that is
activated near 8E5+ dystrophic neurites in FAD
mice. Active JNK, detected with p-JNK antibody,
colocalized with 8E5 in the FAD:JNK3+/+ brain
(white arrows), which was mostly absent in the
FAD:JNK3/ brain. Scale bar represents 75 mm.
(B) A high-magnification view of the plaque
structures that are positive for 8E5 and phospho-
JNK in FAD:JNK3+/+ and FAD:JNK3/ mice.
Scale bar represents 7 mm.
(C) p-JNK signals also associate with 8E5+ plaque
structures in aged primates. Scale bar represents
75 mm.
(D and E) A high-magnification view revealed that
both the signals for p-JNK and p-T668-APP are
found in degenerating neuritic processes that are
positive for 8E5 (white arrows) in FAD:JNK3+/+
mice. The round 8E5 signals are endballs of
damaged neuritic processes and not cell bodies,
as evidenced by the lack of nuclear Toto staining.
Scale bar represents 15 mm.
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presumably linking Kinesin-1 to receptor carrying vesicles, such
as APP (Cavalli et al., 2005; Taru et al., 2002). APP itself has been
known to be transported along the axon via fast axonal transport
(Koo et al., 1990). We interpret these results as suggesting that
JNK3 can potentially phosphorylate APP at T668P in the axon.
Indeed, p-T668P signals were detected from damaged neurites
in FAD:JNK3+/+ mice (Figure 4E), similarly to p-JNK signals.
Unlike p-JNK signals, p-T668P signals were also prominent in
cell bodies (data not shown). Together, these results suggest
that JNK3 becomes activated in damaged and degenerating
neuritic processes, where it can phosphorylate APP and regulate
its processing. It should be noted that active JNK also colocal-
ized with hyperphosphorylated tau in FAD:JNK3+/+ mice (data
not shown).
JNK3 Deletion Results in a Dramatic Reduction in Ab42
Levels and Plaque Loads in FAD Mice
We next analyzed the effect of deleting JNK3 on overall plaque
deposition in FAD mice. In FAD:JNK3/ mice, insoluble Ab42Neuron 75, 824–837, Slevels were reduced dramatically, by
87% at 6 months (n = 8, p = 0.0004) and
70% at 12 months (n = 8, p = 0.005),
compared to those in FAD:JNK3+/+
mice, based on Ab40 and 42-specific
sandwich Elisa analyses of the brain
samples (Figure 5A). Soluble Ab40 and
42 levels were also reduced with JNK3
deletion (data not shown), but levels of
soluble Ab peptides were negligible in
FAD mice. Similar reductions were
observed when the area occupied by pla-
ques was quantified after 6E10 antibody
labeling at 6 months (Figures 5B and
5C): 68% (n = 4, p % 0.01), 71% (n = 4,p% 0.01), and 65% (n = 4, p% 0.05) reductions were found in
the frontal cortex, the subiculum, and the hippocampus, respec-
tively. As evidenced by Thioflavin S staining (Figure 5C), the size
and the number of plaques were also reduced in the frontal
cortex and the hippocampus at 6 months by 58% (n = 4, p %
0.01) and 47% (n = 4, p % 0.01), respectively. Silver staining
also indicated that JNK3 deletion resulted in a significant reduc-
tion in plaques throughout the brain at 6 months (Figure 5D).
More importantly, the number of neurons in layers 5 and 6 of
the frontal cortex was 17% higher in FAD:JNK3/ compared
to that in FAD:JNK3+/+ mice at 12–13 months, although it did
not reach the levels found in non-FAD mice (n = 5–6; Figure 5E).
In line with these data, deletion of JNK3 from FADmice resulted
in a significant increase in long-term retention of fear memories
at 12–13 months (n = 12; Figure 5F). Similarly to NeuN data,
the extent of improvement in cognitive function did not reach
the normal levels found in non-FADmice, although the difference
was not statistically significant. Since modulation of associative
plasticity in the amygdala where fear memories are encoded in-
volves both the hippocampus and prefrontal cortex (Maren andeptember 6, 2012 ª2012 Elsevier Inc. 829
Figure 5. JNK3 Deletion in FAD Results in a Dramatic Reduction in Ab-Peptides and Plaques
(A) JNK3 deletion from FAD results in an 87% and 70% reduction in insoluble Ab-42 levels at 6 and 12 months, respectively. Quantification of Ab-40 and Ab-42
using Elisa assays at 6 and 12 months. Data are represented as means ± SEM; n = 8. p values were calculated by Student’s t test.
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Ab Activates AMPKQuirk, 2004), these results suggest that JNK3 activation affects
cognitive function in FAD mice. Together, these results indicate
that JNK3 plays a critical role in development of AD pathology
by not only regulating Ab peptide production but also
impacting neuronal survival and associative learning capacity
in FAD mice.
We next asked whether JNK3 phosphorylates APP in the
brain, thereby regulating b and/or g cleavage processes, by
preparing whole-cell lysates as well as membrane fractions
from 6-month-old mice. JNK3 indeed phosphorylates APP at
T668P in FAD brains, without affecting the total APP protein
levels (Figure 5G): while the human APP levels in whole-cell
lysates were not very different between FAD:JNK3+/+ and
FAD:JNK3/ mice, p-T668P signals as well as human APP
protein levels were significantly reduced when membrane
fractions were analyzed (Figure 5G). It should be noted that
sw192 antibody is specific to Swedish mutation in human APP
(Haass et al., 1995), thus it was used as a marker for FAD
mice. In particular, p-T668P levels in membrane fractions
were reduced to a much greater extent in a and b CTF than in
the full-length APPwith JNK3 deletion. This finding closely paral-
lels the observation in human AD brains, wherein increased
T668P phosphorylation mainly associated with a and b CTF
and not the full-length APP (Lee et al., 2003). In addition, total
protein levels of a and b CTF were also reduced to a much
greater extent than those in the full-length APP in the membrane
fraction (Figure 5G). These results correlate faithfully with our
Ab42 Elisa results at 6 months. We therefore interpret these
results as suggesting that JNK3 phosphorylates APP preferen-
tially in membranous compartments, such as vesicles/endo-
somes, thereby promoting APP processing. It should be noted
that although BACE1 and PS1 levels were increased in FAD
mice compared to those in normal mice as reported (O’Connor
et al., 2008), JNK3 deletion did not affect their levels greatly
(Figure 5H). Similarly, neither the levels nor the extent of tau
phosphorylation was altered by JNK3 deletion in FAD mice
(data not shown).
A Widespread Translational Block Is a Prominent
Feature in FAD Mice
In a preliminary RNaseq-based transcriptome analysis of
3-month-old FAD mice with and without JNK3 and the control
cortices from JNK3+/+ and JNK3/ mice, we obtained the(B) Quantification of areas that were occupied by plaques in the frontal cortex at
Student’s t test.
(C) Representative images of Ab staining with 6E10 in the cortex at 6months. Scale
the frontal cortex at 6 months. Scale bar represents 75 mm.
(D) JNK3 deletion from FAD results in a significant reduction in plaque loads. Silv
represent 1.5 mm (upper) and 150 mm (lower).
(E) JNK3 deletion in FAD results in an increase in neuronal survival at 12–13months
as means ± SEM. p values were calculated by Student’s t test.
(F) JNK3 deletion in FADmice results in an improvement in cognitive function at 1
represented as means of 8 trials per mouse ± SEM. p values were calculated by
(G) T668 phosphorylation is reduced in FAD:JNK3/ compared to FAD:JNK3+/+
reduced in FAD:JNK3/ compared to FAD:JNK3+/+mice. In contrast, their levels
Also reduced in membrane fractions are p-T668P levels of the full-length APP an
(H) Neither BACE1 and PS1 levels nor the extent of tau phosphorylation were very
was, however, increased in FAD compared to non-FAD controls.results that suggest that there is a general translational block
in FAD:JNK3+/+ mice; genes involved in translation, such as
ribosomes and translation-initiation factors, were dramatically
reduced in FAD:JNK3+/+ compared to JNK3+/+ mice and
JNK3 deletion restored the effect on these genes to nearly
normal levels (data not shown). We therefore tested whether
there is indeed a global translational block in FAD mice by
western blotting cortical lysates with an antibody against phos-
pho-S6235/236 ribosomal protein, a marker for active translation.
Indeed, the p-S6 signal was reduced by 48% in FAD: JNK3+/+
mice, compared to that in the normal mice and FAD:JNK3/
mice (Figures 6A and 6B). Immunohistochemistry with p-S6
antibody also revealed similar findings: both the number of cells
that are positive for p-S6 signals and the intensity of its signals
decreased significantly in the cortex of FAD:JNK3+/+ mice,
compared to those in other genotypes (Figure 6C). It should
also be pointed out that p-RaptorS792 levels were increased
by 4-fold in FAD:JNK3+/+ compared to those in FAD:JNK3/
(Figures 6A and 6B). Since S792 in Raptor is phosphorylated
by AMPK (Gwinn et al., 2008), these results suggest that
AMPK activity is also reduced in FAD:JNK3/ compared to
FAD:JNK3+/+ mice. These results agree also with our culture
data in Figure 1.
UPR Is a Prominent Feature in FAD Mice as well as
in Human AD Cases
Oligomeric Ab42 treatment in hippocampal neurons also
resulted in phosphorylation of Eif2a, albeit to a lower extent
than that by Thapsigargin, suggesting that Ab42 induces ER
stress (Figure 1E). A reduction in the global rate of translation
is one of the earliest events in UPR, which leads to induction
of a widespread secondary response that includes transcrip-
tional activation of the target genes for UPR, namely, apoptotic
as well as survival promoting genes (Ron and Walter, 2007).
Western blotting of a selected set of ER stress transducers,
such as p-Eif2a, ATF4, and PERK, supported the finding that
expression of these proteins was increased by approximately
2-fold in 3-month-old FAD:JNK3+/+ compared to those in
normal and FAD:JNK3/ mice (p < 0.05; Figures 7A and 7B).
More importantly, cortical samples from five AD patients
demonstrated a significant increase in ER stress markers,
including p-Eif2a, ATF4, CHOP, and PERK compared to five
age-matched control cases (Figure 7C). Together, these6 months. Data are represented as means ± SEM. p values were calculated by
bar represents 150 mm. Also shown are the images of Thioflavin S staining from
er-stained sections of the brain at 6 months; plaques appear black. Scale bars
. NeuN+ cells were quantified from cortical layers 5 and 6. Data are represented
2–13 months. Mice were subjected to fear conditioning tests (n = 12). Data are
Student’s t test.
mice. Protein levels of the full-length APP and CTF in membrane fractions are
were similar between the genotypes when whole-cell extracts were prepared.
d CTF.
different between FAD:JNK3+/+ and FAD:JNK3/mice. Tau phosphorylation
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Figure 6. JNK3 Activation Is Integral to FAD Pathology, Regulating
the Translational Block Induced by Inhibition of the mTOR Pathway
(A) Phosphorylation of S6 ribosomal protein, an indicator of active translation is
reduced, while phosphorylation in Raptor at S792, an AMPK phosphorylation
site, was increased in FAD:JNK3+/+ compared to that in other genotypes. Also
shown are control western blots for the JNK3 genotype and FAD genotype:
192SW is specific to the Swedish mutation in human APP.
(B) Quantification of p-S6 and p-Raptor protein levels in (A). y axis on the left is
for p-S6 and the one on the right is for p-Raptor. Data are represented as
means ± SEM. p values were calculated by Student’s t test.
(C) Both the number of cells that express p-S6 and the level of p-S6 immu-
noreactivity was decreased in FAD:JNK3+/+ mice compared to other geno-
types in the cingulate cortex at 3–4 months. Scale bars represent 75 mM.
Neuron
Ab Activates AMPKsuggest that the ER stress response occurs in human AD, and
JNK3 activation may contribute to it.
JNK3 Activation Maintains a Positive Feedback Loop
of Cyclic Ab42 Production
We hypothesized that once UPR is induced, it activates JNK3,
which in turn promotes further APP processing by phosphory-
lating it at T668P. T668P phosphorylation facilitates increased
internalization of the receptor into endosomal vesicles wherein
APP undergoes processing to generate more Ab42. As the
cycle repeats itself, more Ab42 accumulates, exacerbating the
pathology (Figure 8A). To test the hypothesis that translational
block and/or ER stress increases APP processing in a JNK3-
dependent manner, organotypic slices were prepared from
8- to 10-week-old FAD:JNK3+/+ and FAD:JNK3/ mice and832 Neuron 75, 824–837, September 6, 2012 ª2012 Elsevier Inc.treated with the vehicle, 0.5 mM Thapsigargin or 10 nM Rapa-
mycin, for the indicated amounts of time. Both CTF and Ab
peptide levels increased gradually over the 9 hr period in
FAD:JNK3+/+ slices with Thapsigargin as well as Rapamycin
treatments (Figure 8B). These results suggest that ER stress
or inhibiting the mTOR pathway is sufficient to induce Ab
peptide production. Importantly, this increase in APP process-
ing was dependent on JNK3, since the overall CTF and Ab
peptide levels were significantly reduced in FAD:JNK3/ slices
(Figure 8B). These results together indicate that JNK3 activation
is necessary to perpetuate the cycle of translational block via
mTOR, ER stress, JNK3 activation, and further production
of Ab42.
DISCUSSION
Here, we report that JNK3 activation is critical for maintaining
a positive feedback loop that culminates in continued production
of Ab42. This conclusion is supported by a dramatic reduction in
overall Ab42 levels upon deleting JNK3 from FAD mice. Such
a dramatic reduction is not only due to the ability of JNK3 to
phosphorylate APP directly, but also due to the cyclic activation
of JNK3 by a translational block and subsequent UPR that had
been induced by oligomeric Ab42 in the first place.
JNK3 phosphorylates APP at the T668P site in its cytoplasmic
domain both in vitro and in vivo. The fact that JNK or JNK3
phosphorylates APP is also supported by a study, where double
deletion of putative upstream JNK kinases, MKK4 and MKK7,
from another FAD mouse line resulted in a reduction in T668P
phosphorylation (Mazzitelli et al., 2011). T668P phosphorylation
was increased in AD brains, wherein the b-CTF rather than the
full-length APP exhibited increased T668P phosphorylation
compared to the control (Lee et al., 2003). Supporting the notion
that T668 phosphorylation contributes to APP processing,
T668P to A668P mutation reduced Ab peptide generation
in vitro (Lee et al., 2003). Our data also support this view:
When JNK phosphorylated APP at T668P, the amount of CTF
increased. This was in part due to the fact that JNK phosphory-
lation of T668P in APP facilitated rapid internalization of the
receptor as indicated by a reduction in the amount of the full-
length APP on the cell surface. Since JNK3 is not the only kinase
that phosphorylates APP at T668P in vivo as indicated by our
data, and JNK3 can also be activated in the axon under patho-
logical conditions (Falzone et al., 2009; Morfini et al., 2009), we
hypothesize that JNK3 is the predominant kinase that phos-
phorylates APP within particular endosomal compartments in
the axon where APP encounters BACE1 (Abe et al., 2009; Cavalli
et al., 2005).
Structurally, phosphorylation at T668P induces propyl isomer-
ization, converting the p-T668P peptide from trans to cis con-
figuration (Ramelot and Nicholson, 2001). Pin1, a phosphory-
lation-dependent propyl isomerase, indeed binds p-T668P
in vitro, thereby facilitating cis to trans conversion (Pastorino
et al., 2006). Since Pin1 deletion from an AD mouse line resulted
in a 46% increase in Ab peptide production, cis configuration
induced by T668 phosphorylation is believed to render APP
vulnerable to amyloidogenic processing (Pastorino et al., 2006).
Our data and those of Lee et al. (2003) also support the idea
Figure 7. The ER Stress Response Is
a Predominant Feature in Human AD Cases
as well as in FAD
(A) An increase in ER markers is detected in
FAD:JNK3+/+ mice, which becomes reduced as
a result of deleting JNK3.
(B) Quantification of ER markers in (A) (n = 3–4).
Data are represented as means ± SEM. p values
were calculated by Student’s t test. * denotes
p < 0.05.
(C) An increase in the ER stress response in human
AD cases, compared to age-matched control
cases.
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Ab Activates AMPKthat T668P phosphorylation is critical for Ab peptide generation
in vitro. Whether T668P phosphorylation causes greater Ab
peptide generation in vivo is, however, still unresolved. In normal
agedmice, A668P knock-in mutation did not affect bCTF gener-
ation (Sano et al., 2006), leading the authors to conclude that
T668P phosphorylation plays no role in APP processing. Such
a conclusion is premature especially with gain-of-function muta-
tions such as phosphorylation, until the role of T668P phosphor-
ylation is assessed in AD mouse models. A case in point is that
althoughhyperphosphorylation of tau is clearly indicatedaspath-
ologic, deleting tau alone showeda relativelyminor defect in axon
degeneration (Dawson et al., 2001; Go´mez de Barreda et al.,
2010; Harada et al., 1994). It was only when tau was deleted
under an AD background that improvement in cognitive behavior
was observed (Roberson et al., 2007). Although critical experi-
ments are still needed to address whether T668P phosphoryla-
tion causesAPPprocessing in vivo, our study provides additional
support to the idea that T668P phosphorylation significantly
contributes to APP processing in vivo.
We provide compelling evidence that a translational block is
a prominent feature in FAD mice and to some extent in human
AD cases. Since oligomeric Ab42 induced a translational block
in hippocampal neurons in culture, it is highly likely that oligo-
meric Ab42 has a similar effect in vivo. Oligomeric Ab42 is widely
believed to be the central pathologic species that is responsibleNeuron 75, 824–837, Sfor inhibiting LTP and memory formation
in vivo (Cleary et al., 2005; Walsh et al.,
2002). Since inhibiting normal transla-
tional processes by disabling eif2a phos-
phorylation or deleting its kinase, GCN2,
resulted in inhibition of LTP (Costa-Mat-
tioli et al., 2005, 2007), it is tempting to
speculate that such synaptotoxicity
observed with oligomeric Ab42 is likely
to be due to its inhibitory effect on
translation.
Our data indicate that oligomeric Ab42
inhibits translation in part by blocking
the mTOR pathway. Dysregulation of the
mTOR pathway or loss of energy balance
has been identified as causative in normal
aging as well as type 2-diabetes and
obesity (Cohen et al., 2009; Demontis
and Perrimon, 2010; Koo et al., 2005;Mair et al., 2011; Song et al., 2010). Our findings that widespread
disruption of normal energy balance is prominent in FAD mice
and to some extent in human AD cases suggest that in progres-
sive diseases whose symptoms develop over a long period time,
chronic metabolic imbalance becomes a pervasive phenotype.
Our data clearly illustrate that oligomeric Ab42 perturbs energy
homeostasis, as indicated by activation of AMPK, a kinase that
responds to energy imbalance in the cell (Steinberg and Kemp,
2009). AMPK was shown to play a critical role in aging in yeast
and C. elegans, although the loss of snf1p, the yeast homolog
of AMPK, increased the life span (Lin et al., 2001), while mutation
in aak-2, the worm homolog of AMPK, decreased the life exten-
sion induced by stress (Apfeld et al., 2004). Besides this
apparent species-related difference in homolog roles, the role
of AMPK itself in aging appears clear. It is of special interest in
this regard that oligomeric Ab42 activates AMPK, thereby inhib-
iting themTORpathway. Ab peptides are normally produced and
cleared rapidly in human brains (Bateman et al., 2006). It is plau-
sible that normal production of Ab peptides contributes to the
aging process in part by activating AMPK.
AMPK activation was rapid but transient by oligomeric Ab42,
detectable at 10min, but greatly reduced by 3 hr after Ab42 addi-
tion. Although transiently activated, AMPK substrates Raptor
and TSC2 remain phosphorylated up to 16 hr, providing an
explanation for a prolonged translational inhibition. What willeptember 6, 2012 ª2012 Elsevier Inc. 833
Figure 8. Translational Block Exacerbates APP Processing in JNK3-
Dependent Manner
(A) A model of how JNK3 activation exacerbates the development of AD
pathology. We hypothesize that JNK3 is initially activated by death receptors
and/or under certain stress conditions. Once activated, JNK3 phosphorylates
APP at T668P, facilitating APP processing by enhancing its internalization,
which results in greater Ab42 production. Ab42 then blocks translation, leading
to UPR, which activates JNK3. Activated JNK3 will target APP again in
a positive feedback loop, thereby perpetuating a cycle that exacerbates Ab42
production.
(B) Both Thapsigargin and Rapamycin increase Ab42 production in a JNK3-
dependent manner. Organotypic brain slices from FAD:JNK3+/+ and
FAD:JNK3/ were treated with the vehicle, 0.5 mM Thapsigargin, and 10 nM
Rapamycin for the indicated amount of time and the resulting whole-cell
lysates were analyzed for 6E10 Western. In order to facilitate detection of CTF
and Ab peptides, the slices were also treated with 10 mM MG132 at the same
time. Note that both CTF and Ab42 levels were increased in FAD:JNK3+/+
cultures upon treatments compared to those in the vehicle control. This
increase was significantly attenuated in FAD:JNK/ slices.
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Ab Activates AMPKbe the mechanism by which oligomeric Ab42 activates AMPK?
AMPK was shown to be activated by LKB1 (Hawley et al.,
2003; Shaw et al., 2004), CaMKK (Anderson et al., 2008; Hawley
et al., 2005; Hurley et al., 2005; Woods et al., 2005), and TAK1
(Momcilovic et al., 2006). In the nervous system, however,
LKB1 does not seem to serve as a kinase for AMPK, since
AMPKa phosphorylation at T172 was not changed in LKB1 null
mice (Barnes et al., 2007). A likely candidate is CaMKK, since
it is highly expressed in the brain and it associates with AMPK
a and b subunits (Anderson et al., 2008). If that is the case, it is
possible that oligomeric Ab42 itself modulates intracellular
calcium levels, thereby activating CaMKK. It will be of interest
to test whether intracellular calcium levels change with oligo-
meric Ab42 addition in neurons.
Can mTOR activity modulation be developed into a therapy
for AD? This is an attractive idea, since there are already many
FDA-approved drugs that were designed to target the mTOR
pathways for treating other progressive metabolic diseases.
Although attractive, the idea appears too premature at the
present time mainly because the role of the mTOR pathway in
AD is not fully understood. For instance, some reported improve-
ment in cognitive function and neuronal toxicity with Rapamycin
administration (Berger et al., 2006; Bove´ et al., 2011; Caccamo
et al., 2010; Khurana et al., 2006; Spilman et al., 2010), while
others reported the opposite (Lafay-Chebassier et al., 2005).834 Neuron 75, 824–837, September 6, 2012 ª2012 Elsevier Inc.Similarly, the reports vary as to whether there is an inhibition or
activation of the mTOR pathway in AD mouse models and/or
human cases (Caccamo et al., 2011; Ma et al., 2010). Our data
indicate that there is a significant translational block early in
FADmice. This notion was also supported by a global transcrip-
tome analysis via RNaseq, which demonstrated a dramatic
reduction in transcripts for ribosomes and elongation factors
in FAD compared to the wild-type mice (data not shown). It is
possible that the use of different animal models at different
ages in each study contributed to the opposite outcomes.
It seems safe to surmise that before one takes further steps to
alter the mTOR pathway or AMPK activity in pursuit of a treat-
ment for AD, more systematic and consistent analyses are
necessary.
In conclusion, our findings suggest that JNK3 activation is
central to the development of AD pathology by exacerbating
metabolic stress that is induced by Ab42 accumulation. This
study thus identifies JNK3 as a promising new target of thera-
peutic intervention for Alzheimer’s disease.
EXPERIMENTAL PROCEDURES
Human Samples
Tissues from the frontal cortex were obtained through UCSD Experimental
Neuropath Laboratory.
Mouse Breeding
FAD mice in B6/SJL F1 hybrid background were initially crossed with JNK3
in knockout mice in B6 background to obtain FAD:JNK3+/ and control
nontransgenic:JNK3+/. This study was approved by the IACUC of the Ohio
State University.
Rat Hippocampal Neuron Cultures
The hippocampal neurons were isolated from E18 rat embryos and cultured
for 7 days in Neurobasal medium supplemented with B27 and 2 mM
glutamine.
Organotypic Slice Preparations
Organotypic slices 500 mm thick were prepared according to (del Rı´o and
Soriano, 2010) from 12- to 14-week-old FAD:JNK+/+ and FAD:JNK3/ mice.
JNK3 Immunoprecipitation/Kinase Assays
The lysates from hippocampal neurons were subjected to immunoprecipita-
tionwith JNK3 antibody, and the immune complexes were used in kinase reac-
tions using GST-c-jun as a substrate as described (Li et al., 2007).
Tissue Preparation for Ab40 and 42 Elisa
Brain tissues that contain the cortex, the hippocampus, the septum, and the
striatum were used to extract proteins using 70% formic acid.
Preparations of Crude Membrane Fractions
Brain tissues were processed to obtain membrane and soluble fractions for
biochemical analyses as described (Pastorino et al., 2006).
Quantification of Plaque Areas and the Numbers of Neurons
For the quantification of the areas occupied by plaques, two 60 mm floating
sections from the bregma positions from +0.26 to +0.5 for the frontal cortex
were processed for staining with 6E10 (n = 4).
Silver Staining
Coronal sections of the brains (60 mm) were processed for silver staining using
a FD NeuroSilver kit from FD Neurotechnologies as directed by the
manufacturer.
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